Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05450198 · ClinicalTrials.gov registry record · Phase 1
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
A Phase 1 study of Dermatitis, Atopic, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 19
- Study locations
NCT05450198: Completed Phase 1 study of Dermatitis, Atopic, sponsored by Merck Sharp & Dohme.
NCT05450198 is a Phase 1 study of Dermatitis, Atopic that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 72 participants, below the 395-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (82% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05450198, a Phase 1 study of Dermatitis, Atopic, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 19
- Study locations
Study Summary
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MK-6194
Study Locations (19)
Florida
- Miami Dermatology and Laser Research ( Site 0025) - Miami
- Global Health Research Center, Inc. ( Site 0005) - Miami Lakes
- Genesis Clinical Research, LLC ( Site 0004) - Tampa
- ForCare Clinical Research ( Site 0003) - Tampa
Texas
- North Texas Center for Clinical Research ( Site 0028) - Frisco
- Progressive Clinical Research ( Site 0022) - San Antonio
- Complete Dermatology ( Site 0023) - Sugar Land
Arkansas
- Arkansas Research Trials-Clinical Trials ( Site 0002) - North Little Rock
Georgia
- Advanced Medical Research, PC. ( Site 0027) - Sandy Springs
Minnesota
- AXIS Clinicals ( Site 0029) - Dilworth
Ohio
- Remington Davis Clinical Research ( Site 0021) - Columbus
Pennsylvania
- Paddington Testing Company ( Site 0010) - Philadelphia
Washington
- Premier Clinical Research ( Site 0026) - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 1 |
What the finished NCT05450198 record still lists
NCT05450198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 395-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05450198 lists 19 locations in 14 states (Florida, Texas, Arkansas).
Frequently Asked Questions
What is clinical trial NCT05450198 about?
NCT05450198 is a clinical study titled "Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)". The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
What is the current status of trial NCT05450198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-08-08. Estimated completion is 2024-05-22.
What conditions does trial NCT05450198 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT05450198?
The interventions under investigation include: Placebo (BIOLOGICAL), MK-6194 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05450198?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05450198 being conducted?
This trial has 19 study locations across Arkansas, Florida, Georgia, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05450198's enrollment target sits among peer trials
72 24th of 29 higher than 6 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate ASN008 Topical Gel (TG)
COMPLETED · Phase 1
-
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
COMPLETED · Phase 1
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI